A detailed study on Biologics market complied by primary and secondary research and validated by industry experts. If you are planning to understand the Biologics market in and out, then this is a must have report. You will also get free analyst support with this report.
Biologics market is one of the markets, where investors have shown great interest. As per the research the market is expected to grow with a CAGR of XX% in coming years. Biologics Market Sizes, Shares, Prices, Trends, and Forecasts have been derived from an in-depth study of the current scenarios in the. This report is based on both value and volume (Where applicable).
*This is a smart report which can be customized according to your need.
Highlights Of The Report:
1. Market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends.
3. Historical data and forecast.
4. Estimations for the forecast period between 2020 and 2026.
5. Developments and trends in the market.
6. By Type:
Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense
RNAi
7. By Application:
Infectious Diseases
Oncology
Immunology
Autoimmune Diseases
8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.Overview of the regional outlook of the market:
- The report offers information about the regions in the market, which is further divided into sub-regions and countries.
- In addition to the market share of each country and sub-region, information regarding lucrative opportunities is included in this chapter of the report.
- Share and market growth rate of each region, country, and sub-region are mentions in this chapter of the report during the estimated time period.
Companies profiled in this report:
1) Eli Lilly & Company
2) Samsung Biologics
3) F Hoffman La Roche
4) Celltrion
5) Addgene
6) Amgen
7) Abbvie Inc.
8) Sanofi
9) Pfizer Inc.
10) Merck & Co. Inc.
11) Novo Nordisk A/S
12) Johnson & Johnson Services Inc.345*Additional companies can be added in Biologics market report as a part of free customization. Feel free to get in touch with our research analyst.
This chapter of the report comprises various key companies operating in the global market. This helps the reader understand the competitive landscape, including the strategies adopted by the players to stay in the competitive market.
- Market Share
- Company Profile
- Business Information
- SWOT Analysis
- Strategies
Reasons To Purchase The Biologics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
- Moreover, we provide data support, in the excel format, and 1-year free analyst support.
Frequently Asked Questions?
Biologics are medications that are derived from living organisms. This means that they must be made in a way that does not involve the use of chemical synthesis.
Some of the key players operating in the biologics market are Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion, Addgene, Amgen, Abbvie Inc., Sanofi, Pfizer Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biologics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biologics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biologics Market - Supply Chain
4.5. Global Biologics Market Forecast
4.5.1. Biologics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biologics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Biologics Market Absolute $ Opportunity
5. Global Biologics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Biologics Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies
5.3.2. Vaccines
5.3.3. Recombinant Proteins
5.3.4. Antisense
5.3.5. RNAi
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Biologics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Biologics Market Size and Volume Forecast by Application
6.3.1. Infectious Diseases
6.3.2. Oncology
6.3.3. Immunology
6.3.4. Autoimmune Diseases
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Biologics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Biologics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Biologics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Biologics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Biologics Demand Share Forecast, 2019-2026
9. North America Biologics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Biologics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Biologics Market Size and Volume Forecast by Application
9.4.1. Infectious Diseases
9.4.2. Oncology
9.4.3. Immunology
9.4.4. Autoimmune Diseases
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Biologics Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies
9.7.2. Vaccines
9.7.3. Recombinant Proteins
9.7.4. Antisense
9.7.5. RNAi
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Biologics Demand Share Forecast, 2019-2026
10. Latin America Biologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Biologics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Biologics Market Size and Volume Forecast by Application
10.4.1. Infectious Diseases
10.4.2. Oncology
10.4.3. Immunology
10.4.4. Autoimmune Diseases
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Biologics Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies
10.7.2. Vaccines
10.7.3. Recombinant Proteins
10.7.4. Antisense
10.7.5. RNAi
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Biologics Demand Share Forecast, 2019-2026
11. Europe Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Biologics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Biologics Market Size and Volume Forecast by Application
11.4.1. Infectious Diseases
11.4.2. Oncology
11.4.3. Immunology
11.4.4. Autoimmune Diseases
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Biologics Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies
11.7.2. Vaccines
11.7.3. Recombinant Proteins
11.7.4. Antisense
11.7.5. RNAi
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Biologics Demand Share, 2019-2026
12. Asia Pacific Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Biologics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Biologics Market Size and Volume Forecast by Application
12.4.1. Infectious Diseases
12.4.2. Oncology
12.4.3. Immunology
12.4.4. Autoimmune Diseases
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Biologics Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies
12.7.2. Vaccines
12.7.3. Recombinant Proteins
12.7.4. Antisense
12.7.5. RNAi
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Biologics Demand Share, 2019-2026
13. Middle East & Africa Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Biologics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Biologics Market Size and Volume Forecast by Application
13.4.1. Infectious Diseases
13.4.2. Oncology
13.4.3. Immunology
13.4.4. Autoimmune Diseases
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Biologics Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies
13.7.2. Vaccines
13.7.3. Recombinant Proteins
13.7.4. Antisense
13.7.5. RNAi
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Biologics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Biologics Market: Market Share Analysis
14.2. Biologics Distributors and Customers
14.3. Biologics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly & Company
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Samsung Biologics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F Hoffman La Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celltrion
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Addgene
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Amgen
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Abbvie Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Merck & Co. Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Novo Nordisk A/S
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Johnson & Johnson Services Inc.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook